BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation

NYSE:BIO • US0905722072

Current stock price

281.825 USD
+3.07 (+1.1%)
Last:

This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. BIO Profitability Analysis

1.1 Basic Checks

  • In the past year BIO was profitable.
  • In the past year BIO had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
  • BIO had a positive operating cash flow in each of the past 5 years.
BIO Yearly Net Income VS EBIT VS OCF VS FCFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • The Return On Assets of BIO (7.18%) is better than 87.50% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.20%, BIO belongs to the top of the industry, outperforming 82.14% of the companies in the same industry.
  • BIO has a Return On Invested Capital of 2.02%. This is in the better half of the industry: BIO outperforms 64.29% of its industry peers.
  • BIO had an Average Return On Invested Capital over the past 3 years of 2.32%. This is significantly below the industry average of 11.80%.
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROIC 2.02%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
BIO Yearly ROA, ROE, ROICBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • BIO has a better Profit Margin (29.42%) than 98.21% of its industry peers.
  • BIO's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 10.30%, BIO is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BIO has declined.
  • BIO's Gross Margin of 52.01% is fine compared to the rest of the industry. BIO outperforms 62.50% of its industry peers.
  • BIO's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
BIO Yearly Profit, Operating, Gross MarginsBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIO Health Analysis

2.1 Basic Checks

  • BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • BIO has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BIO has been reduced compared to 5 years ago.
  • BIO has a better debt/assets ratio than last year.
BIO Yearly Shares OutstandingBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
BIO Yearly Total Debt VS Total AssetsBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • BIO has an Altman-Z score of 3.13. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.13, BIO is doing good in the industry, outperforming 67.86% of the companies in the same industry.
  • BIO has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as BIO would need 3.21 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.21, BIO belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
  • A Debt/Equity ratio of 0.16 indicates that BIO is not too dependend on debt financing.
  • The Debt to Equity ratio of BIO (0.16) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Altman-Z 3.13
ROIC/WACC0.19
WACC10.49%
BIO Yearly LT Debt VS Equity VS FCFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • BIO has a Current Ratio of 5.62. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
  • BIO has a Current ratio of 5.62. This is amongst the best in the industry. BIO outperforms 83.93% of its industry peers.
  • BIO has a Quick Ratio of 4.19. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
  • BIO's Quick ratio of 4.19 is fine compared to the rest of the industry. BIO outperforms 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.19
BIO Yearly Current Assets VS Current LiabilitesBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIO Growth Analysis

3.1 Past

  • The earnings per share for BIO have decreased by -3.78% in the last year.
  • Measured over the past years, BIO shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.19% on average per year.
  • Looking at the last year, BIO shows a small growth in Revenue. The Revenue has grown by 0.65% in the last year.
  • The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%

3.2 Future

  • BIO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
  • The Revenue is expected to grow by 2.54% on average over the next years.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year2.04%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIO Yearly Revenue VS EstimatesBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO Yearly EPS VS EstimatesBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 28.41 indicates a quite expensive valuation of BIO.
  • Compared to the rest of the industry, the Price/Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 69.64% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (25.58), we can say BIO is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 27.17, the valuation of BIO can be described as expensive.
  • Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 67.86% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.81, BIO is valued at the same level.
Industry RankSector Rank
PE 28.41
Fwd PE 27.17
BIO Price Earnings VS Forward Price EarningsBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 83.93% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.31
EV/EBITDA N/A
BIO Per share dataBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of BIO may justify a higher PE ratio.
PEG (NY)6.21
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIO Dividend Analysis

5.1 Amount

  • BIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO Fundamentals: All Metrics, Ratios and Statistics

BIO-RAD LABORATORIES-A

NYSE:BIO (4/1/2026, 11:37:47 AM)

281.825

+3.07 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners90.44%
Inst Owner Change-2.09%
Ins Owners8.17%
Ins Owner Change0%
Market Cap7.61B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target341.7 (21.25%)
Short Float %5.5%
Short Ratio3.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)0%
PT rev (3m)-5.63%
EPS NQ rev (1m)-6.43%
EPS NQ rev (3m)-26.33%
EPS NY rev (1m)1.2%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)-0.49%
Valuation
Industry RankSector Rank
PE 28.41
Fwd PE 27.17
P/S 2.94
P/FCF 20.31
P/OCF 14.29
P/B 1.02
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)9.92
EY3.52%
EPS(NY)10.37
Fwd EY3.68%
FCF(TTM)13.88
FCFY4.92%
OCF(TTM)19.72
OCFY7%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)6.21
PEG (5Y)N/A
Graham Number248.27
Profitability
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROCE 2.65%
ROIC 2.02%
ROICexc 2.38%
ROICexgc 2.62%
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
FCFM 14.5%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.1%
Interest Coverage -5.71
Cash Conversion N/A
Profit Quality 49.3%
Current Ratio 5.62
Quick Ratio 4.19
Altman-Z 3.13
F-Score5
WACC10.49%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year2.04%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%

BIO-RAD LABORATORIES-A / BIO Fundamental Analysis FAQ

What is the fundamental rating for BIO stock?

ChartMill assigns a fundamental rating of 5 / 10 to BIO.


Can you provide the valuation status for BIO-RAD LABORATORIES-A?

ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Fairly Valued.


How profitable is BIO-RAD LABORATORIES-A (BIO) stock?

BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 6 / 10.


What is the valuation of BIO-RAD LABORATORIES-A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 28.41 and the Price/Book (PB) ratio is 1.02.


Can you provide the expected EPS growth for BIO stock?

The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.57% in the next year.